CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Based on these observations, our primary aims were to directly assess whether the inhibition of the pro-apoptotic effect of imatinib by activated T cell secretome depends on IFNγ, and to characterize the effect of IFNγ on the imatinib-induced apoptosis of CML cells, including primary human CD34+ CML stem/progenitor cells.